西格列汀潜在用途研究进展

摘要/Abstract

摘要： 西格列汀是一种高度选择性的二肽基肽酶-4（dipeptidyl peptidase-4，DPP-4）抑制剂，作为同类药物中首个被批准用于治疗2型糖尿病的药物，具有良好的有效性、耐受性，低血糖及体重增加等不良反应发生率低。近年来随着对西格列汀研究的越来越多，该药物在不同情况下的更多作用相继被发现。西格列汀除了有降低血糖的作用以外还有抗炎作用、抗肿瘤作用、肾脏保护作用、心血管保护作用、促组织再生作用。该文就西格列汀在各领域的作用进行综述，从而为相关疾病诊疗和组织再生的研究提供参考。

关键词: 西格列汀, 抗炎, 抗肿瘤, 肾脏保护作用, 心血管保护作用, 组织再生作用

Abstract: Sitagliptin is a highly selective dipeptidyl peptidase-4(DPP-4) inhibitor. As the first drug of its kind approved for the treatment of type 2 diabetes, it has the advantages of good efficacy, tolerance, and a low occurrence rate of hypoglycemia and weight gain. In recent years, with more and more studies on sitagliptin conducted, more effects of the drug in different situations have been discovered. In addition to the role of lowering blood sugar, sitagliptin also has the effects of anti-inflammation, anti-tumor, potential renal protection, cardiovascular protection, and tissue regeneration. This article reviews the roles of sitagliptin in various fields, which will provide a reference for the diagnosis and treatment of related diseases and tissue regeneration.

Key words: sitagliptin, anti-inflammation, anti-tumor, renal protection, cardiovascular protection, tissue regeneration

中图分类号:

R780.1

刘相葛少华. 西格列汀潜在用途研究进展[J]. 口腔医学, 2021, 41(1): 76-82.

Xiang LIU. Research progress of the potential use of sitagliptin[J]. Stomatology, 2021, 41(1): 76-82.

参考文献 64

[1]	Nassar H, Kantarci A, Van Dyke TE.Diabetic periodontitis: a model for activated innate immunity and impaired resolution of inflammation[J].Periodontol 2000, 2007, 43:233-244
[2]	Saeedi P, Petersohn I, Salpea P, et al.Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition [J].Diabetes Res Clin Pract, 2019, 157:107843-
[3]	Arnolds S, Dellweg S, Clair J, et al.Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study[J].Diabetes Care, 2010, 33(7):1509-1515
[4]	Zerilli T, Pyon EY.Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus[J].Clin Ther, 2007, 29(12):2614-2634
[5]	Makdissi A, Ghanim H, Vora M, et al.Sitagliptin exerts an antinflammatory action[J].J Clin Endocrinol Metab, 2012, 97(9):3333-3341
[6]	Bock G, Dalla Man C, Micheletto F, et al.The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose[J].Clin Endocrinol (Oxf), 2010, 73(2):189-196
[7]	Ohnuma K, Hatano R, Komiya E, et al.A novel role for CD26/dipeptidyl peptidase IV as a therapeutic target[J].Front Biosci (Landmark Ed), 2018, 23:1754-1779
[8]	Ohnuma K, Takahashi N, Yamochi T, et al.Role of CD26/dipeptidyl peptidase IV in human T cell activation and function[J].Front Biosci, 2008, 13:2299-2310
[9]	Anderluh M, Kocic G, Tomovic K, et al.Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors[J].Pharmacol Ther, 2016, 167:100-107
[10]	Holst JJ.The physiology of glucagon-like peptide 1[J].Physiol Rev, 2007, 87(4):1409-1439
[11]	Mentlein R.Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides[J].Regul Pept, 1999, 85(1):9-24
[12]	Garg K, Tripathi CD, Kumar S.Clinical review of sitagliptin: a DPP-4 inhibitor[J].J Assoc Physicians India, 2013, 61(9):645-649
[13]	Zhuge F, Ni Y, Nagashimada M, et al.DPP-4 Inhibition by Linagliptin Attenuates Obesity-Related Inflammation and Insulin Resistance by Regulating M1M2 Macrophage Polarization[J].Diabetes, 2016, 65(10):2966-2979
[14]	Satoh-Asahara N, Sasaki Y, Wada H, et al.A dipeptidyl peptidase-4 inhibitor,sitagliptin,exerts anti-inflammatory effects in type 2 diabetic patients[J].Metabolism, 2013, 62(3):347-351
[15]	Hu X, Liu S, Liu X, et al.DPP-4 (CD26) inhibitor sitagliptin exerts anti-inflammatory effects on rat insulinoma (RINm) cells via suppressing NF-kappaB activation[J].Endocrine, 2017, 55(3):754-763
[16]	Esposito G, Cappetta D, Russo R, et al.Sitagliptin reduces inflammation,fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction[J].Br J Pharmacol, 2017, 174(22):4070-4086
[17]	Boonacker E, Van Noorden CJ.The multifunctional or moonlighting protein CD26DPPIV[J].Eur J Cell Biol, 2003, 82(2):53-73
[18]	Havre PA, Abe M, Urasaki Y, et al.The role of CD26/dipeptidyl peptidase IV in cancer[J].Front Biosci, 2008, 13:1634-1645
[19]	Stecca BA, Nardo B, Chieco P, et al.Aberrant dipeptidyl peptidase IV (DPP IVCD26) expression in human hepatocellular carcinoma[J].J Hepatol, 1997, 27(2):337-345
[20]	Roesch A, Wittschier S, Becker B, et al.Loss of dipeptidyl peptidase IV immunostaining discriminates malignant melanomas from deep penetrating nevi[J].Mod Pathol, 2006, 19(10):1378-1385
[21]	Kajiyama H, Kikkawa F, Suzuki T, et al.Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma[J].Cancer Res, 2002, 62(10):2753-2757
[22]	Dimitrova M, Ivanov I, Todorova R, et al.Comparison of the activity levels and localization of dipeptidyl peptidase IV in normal and tumor human lung cells[J].Tissue Cell, 2012, 44(2):74-79
[23]	Choi HJ, Kim JY, Lim SC, et al.Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression[J].Br J Pharmacol, 2015, 172(21):5096-5109
[24]	Jiang W, Wen D, Cheng Z, et al.Effect of sitagliptin,a DPP-4 inhibitor,against DENA-induced liver cancer in rats mediated via NF-kappaB activation and inflammatory cytokines[J].J Biochem Mol Toxicol, 2018, 32(12):e22220-
[25]	Amritha CA, Kumaravelu P, Chellathai DD.Evaluation of Anti Cancer Effects of DPP-4 Inhibitors in Colon Cancer- An Invitro Study[J].J Clin Diagn Res, 2015, 9(12):FC14-FC16
[26]	Yang X, Zhang X, Wu R, et al.DPPIV promotes endometrial carcinoma cell proliferation,invasion and tumorigenesis[J].Oncotarget, 2017, 8(5):8679-8692
[27]	Kabel AM, Atef A, Estfanous RS.Ameliorative potential of sitagliptin and/or resveratrol on experimentally-induced clear cell renal cell carcinoma[J].Biomed Pharmacother, 2018, 97:667-674
[28]	Chawla A, Chawla R, Jaggi S.Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum?[J].Indian J Endocrinol Metab, 2016, 20(4):546-551
[29]	Mima A.Incretin-Based Therapy for Prevention of Diabetic Vascular Complications[J].J Diabetes Res, 2016, 2016:1379274-
[30]	Hasan AA, Hocher B.Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy[J].J Mol Endocrinol, 2017, 59(1):R1-R10
[31]	Abdelrahman RS.Sitagliptin exerts anti-apoptotic effect in nephrotoxicity induced by cisplatin in rats[J].Naunyn Schmiedebergs Arch Pharmacol, 2017, 390(7):721-731
[32]	Vaghasiya J, Sheth N, Bhalodia Y, et al.Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes[J].Regul Pept, 2011, 166(1-3):48-54
[33]	Ren X, Liu G, Wang Y, et al.Influence of Dipeptidyl Peptidase-IV Inhibitor Sitagliptin on Extracellular Signal-Regulated Kinases 12 Signaling in Rats with Diabetic Nephropathy[J].Pharmacology, 2017, 100(1-2):1-13
[34]	Nathan DM.Diabetes: Advances in Diagnosis and Treatment[J].JAMA, 2015, 314(10):1052-1062
[35]	Deacon CF.Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review[J].Diabetes Obes Metab, 2011, 13(1):7-18
[36]	Rehman MB, Tudrej BV, Soustre J, et al.Efficacy and safety of DPP-4 inhibitors in patients with type 2 diabetes: Meta-analysis of placebo-controlled randomized clinical trials[J].Diabetes Metab, 2017, 43(1):48-58
[37]	Green JB, Bethel MA, Armstrong PW, et al.Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes[J].N Engl J Med, 2015, 373(3):232-242
[38]	Mccormick LM, Kydd AC, Read PA, et al.Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease[J].Circ Cardiovasc Imaging, 2014, 7(2):274-281
[39]	Connelly KA, Zhang Y, Advani A, et al.DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes[J].Cardiovasc Ther, 2013, 31(5):259-267
[40]	Beckman JA, Creager MA, Libby P.Diabetes and atherosclerosis: epidemiology,pathophysiology,and management[J].JAMA, 2002, 287(19):2570-2581
[41]	Omoto S, Taniura T, Nishizawa T, et al.Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus[J].Diabetes Metab Syndr Obes, 2015, 8:339-345
[42]	Matsubara J, Sugiyama S, Sugamura K, et al.A dipeptidyl peptidase-4 inhibitor,des-fluoro-sitagliptin,improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice[J].J Am Coll Cardiol, 2012, 59(3):265-276
[43]	Liu L, Liu J, Wong WT, et al.Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism[J].Hypertension, 2012, 60(3):833-841
[44]	Wang H, Zhou Y, Guo Z, et al.Sitagliptin Attenuates Endothelial Dysfunction of Zucker Diabetic Fatty Rats: Implication of the Antiperoxynitrite and Autophagy[J].J Cardiovasc Pharmacol Ther, 2018, 23(1):66-78
[45]	Tang ST, Su H, Zhang Q, et al.Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-kappaBIkappaBalpha system through the activation of AMP-activated protein kinase[J].Int J Mol Med, 2016, 37(6):1558-1566
[46]	Janowski M.Functional diversity of SDF-1 splicing variants[J].Cell Adh Migr, 2009, 3(3):243-249
[47]	Liekens S, Schols D, Hatse S.CXCL12-CXCR4 axis in angiogenesis,metastasis and stem cell mobilization[J].Curr Pharm Des, 2010, 16(35):3903-3920
[48]	Kowalski K, Kolodziejczyk A, Sikorska M, et al.Stem cells migration during skeletal muscle regeneration - the role of Sdf-1Cxcr4 and Sdf-1Cxcr7 axis[J].Cell Adh Migr, 2017, 11(4):384-398
[49]	Ji W, Yang F, Ma J, et al.Incorporation of stromal cell-derived factor-1alpha in PCLgelatin electrospun membranes for guided bone regeneration[J].Biomaterials, 2013, 34(3):735-745
[50]	Negro S, Lessi F, Duregotti E, et al.CXCL12alphaSDF-1 from perisynaptic Schwann cells promotes regeneration of injured motor axon terminals[J].EMBO Mol Med, 2017, 9(8):1000-1010
[51]	Kitaori T, Ito H, Schwarz EM, et al.Stromal cell-derived factor 1CXCR4 signaling is critical for the recruitment of mesenchymal stem cells to the fracture site during skeletal repair in a mouse model[J].Arthritis Rheum, 2009, 60(3):813-823
[52]	Kim DS, Kim YS, Bae WJ, et al.The role of SDF-1 and CXCR4 on odontoblastic differentiation in human dental pulp cells[J].Int Endod J, 2014, 47(6):534-541
[53]	Du L, Yang P, Ge S.Stromal cell-derived factor-1 significantly induces proliferation,migration,and collagen type I expression in a human periodontal ligament stem cell subpopulation[J].J Periodontol, 2012, 83(3):379-388
[54]	Baticic Pucar L, Pernjak Pugel E, Detel D, et al.Involvement of DPP IVCD26 in cutaneous wound healing process in mice[J].Wound Repair Regen, 2017, 25(1):25-40
[55]	Liang J, Leung KK, Lam SY, et al.Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells[J].Diabetes Obes Metab, 2012, 14(9):842-851
[56]	Jungraithmayr W, De Meester I, Matheeussen V, et al.CD26DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation[J].Eur J Cardiothorac Surg, 2012, 41(5):1166-1173
[57]	Li CJ, Sun B, Fang QH, et al.Saxagliptin Induces beta-Cell Proliferation through Increasing Stromal Cell-Derived Factor-1alpha In Vivo and In Vitro[J].Front Endocrinol (Lausanne), 2017, 8:326-
[58]	Papazafiropoulou AK, Papanas N, Trikkalinou A, et al.The Oral Dipeptidyl-Peptidase-4 Inhibitor Sitagliptin Increases Circulating Levels Of Stromal-Derived Factor-1 Alpha[J].Exp Clin Endocrinol Diabetes, 2018, 126(6):367-370
[59]	Huang CY, Shih CM, Tsao NW, et al.Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells[J].Br J Pharmacol, 2012, 167(7):1506-1519
[60]	Fadini GP, Boscaro E, Albiero M, et al.The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha[J].Diabetes Care, 2010, 33(7):1607-1609
[61]	Yu G, Liu P, Shi Y, et al.Sitagliptin Stimulates Endothelial Progenitor Cells to Induce Endothelialization in Aneurysm Necks Through the SDF-1/CXCR4/NRF2 Signaling Pathway[J].Front Endocrinol (Lausanne), 2019, 10:823-
[62]	Gaudin-Audrain C, Irwin N, Mansur S, et al.Glucose-dependent insulinotropic polypeptide receptor deficiency leads to modifications of trabecular bone volume and quality in mice[J].Bone, 2013, 53(1):221-230
[63]	Hamann C, Kirschner S, Gunther KP, et al.Bone,sweet bone--osteoporotic fractures in diabetes mellitus[J].Nat Rev Endocrinol, 2012, 8(5):297-305
[64]	Glorie L, Behets GJ, Baerts L, et al.DPP IV inhibitor treatment attenuates bone loss and improves mechanical bone strength in male diabetic rats[J].Am J Physiol Endocrinol Metab, 2014, 307(5):E447-E455